What do pregnancy data suggest about the risk of major congenital malformations with levetiracetam monotherapy?

Postmarketing data from more than 1,800 pregnancies exposed to levetiracetam monotherapy, including more than 1,500 first-trimester exposures, do not suggest an increased risk of major congenital malformations.